Welcome to CenterNet's CME testing site for Breast Cancer: Women at Risk, Prevention Strategies and Current Treatment Options

This continuing educational activity consists of a 1 hour video with a CME post test and evaluation form.
This activity should take about 1.5 hours to complete. To qualify for credit and receive a Certificate of Completion, the participant should:
1. review the objectives
2. watch the video
3. complete the viewer evaluation, post test, and CME application which are all available online at this website.
If you achieve a score of 70% or more, you will be able to print your CME certificate from this online site.
If you don't manage to achieve a passing score, you are welcome to try again.
If you have any difficulty printing out your certificate, please email cme@centernet-tv.com with your problem.
CME credit is available until May 2004 for this program. No credit will be given after that date.
Good Luck!

Objectives for Breast Cancer: Women at Risk, Prevention Strategies and Current Treatment Options

• Describe trends in breast cancer incidence and mortality in the U.S. by ethnic group and age
• Identify selective exposures related to risk of breast cancer
• Identify women at high risk of developing invasive breast cancer and strategies to decrease this risk
• Discuss recommendations for adjuvant treatment of breast cancer
• Discuss future directions in breast cancer research


Faculty Disclosures

Name

Grantee/Research

Consultant Speakers Bureau

Advisory Board
JoAnne Zujewski, MD Eli Lilly Clinical Trial Agreement none none
Sandra M. Swain MD none none none
Michele Forman,PhD,MS none none none

Accreditation Information

The NIH/FAES is accredited by the Accreditation Council for Continuing Medical Education to sponsor continuing medical education for physicians.

The NIH/FAES designates this educational activity for a maximum of 1.5 hours in category 1 credit for each program (total of 15 hours for entire series) towards the AMA Physician’s Recognition Award. Each physician should claim only those hours of credit actually spent in the educational activity.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint sponsorship of the National Institutes of Health/Foundation for Advanced Education in the Sciences (NIH/FAES) and The Association of Academic Health Centers (AHC).  The views presented here are those of the Roundtable panel members and not necessarily those of CenterNet, the producer, the Association of Academic Health Centers, the National Cancer Institute of the National Institutes of Health, or any government agency. Neither the National Cancer Institute of the National Institutes of Health, nor any other government agency endorse any particular drug or product. Before using or prescribing any product discussed in the video, clinicians should consult the full prescribing information.
 

Needs Assessment
According to an article in The Washington Post on January 1, 2002, there were 192,200 new cases of breast cancer in the US in 2001. This program will address the epidemiology, risk, prevention strategies and new treatment options for breast cancer. This program is timely as the results of several important research trials in breast cancer risk, prevention and treatment have been published in the last few years. It is important to incorporate knowledge learned from these studies into clinical practice and inform physicians of new developments.


References for further study

Collaborative Group on Hormonal Factors in Breast Cancer: Lancet 1996; 347-1713-27.

Cummings SR, Eckert S, Krueger KA, Grady D, Powles TJ, Cauley JA, Norton L, Nickelsen T, Bjarnason NH, Morrow M, Lippman ME, Black D, Glusman JE, Costa A, Jordan VC. Related articles. The effect of raloxifene on risk of breast cancer in postmenopausal women; results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation. JAMA. 1999 Jun 16;28(23):2189-97. PMID: 10376571 (PubMed - indexed for MEDLINE)

Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L., Wolmark N. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. Journal of the National Cancer Institute 1998 Sep 16;90(18):1371-88

Goldhirsch A, Glick JH, Gelber, RD, Coates AS, Senn HJ, et al. Meeting highlights: International consensus panel on the treatment of primary breast cancer. Journal of Clinical Oncology 2001, Vol. 19, Sept. 15, 2001, 3817-27.

Hartmann LC, Sellers TA, Schaid DJ, Frank TS, Soderberg CL, Sitta DL, Frost MH, Grant CS, Donohue JH, Woods JE, McDonnell SK, Vockley CW, Deffenbaugh A, Couch FJ, Jenkins RB. Related Articles: Efficacy of bilateral prophylactic mastectomy in BRCA1 and BRCA2 gene mutation carriers. Journal of the National Cancer Institute 2001 Nov 7;93(21):1633-7 PMID: 11698567 (PubMed - indexed for MEDLINE)

Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancer with recent increasing trends. Journal of the National Cancer Institute 2001;93:824-42.

International agency for research in cancer Handbooks of cancer prevention: Volume 6: weight control and physical activity. IARC Press 2002.

Jernstrom et al. Genetic factors related to racial variation in plasma levels of insulin-like growth factor-1: Implications for premenopausal breast cancer risk. Molecular Genetics and Metabolism 2001;72: 144-54.


King MC, Wieand S, Hale K, Lee M, Walsh T, Owens, K, Tait J, Ford L, Dunn BK, Costantino J, Wickerham L, Wolmark N, Fisher B. Related Articles. Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. JAMA. 2001 Nov 14;286(18):2251-6. PMID: 11710890 (PubMed - indexed for MEDLINE)


McDonnell SK, Schaid DJ, Myers JL, Grant CS, Donohue JH, Woods JE, Frost MH,
Johnson JL, Sitta DL, Slezak JM, Crotty TB, Jenkins RB, Seller TA, Hartmann LC. Related articles. Efficacy of contralateral prophylactic mastectomy in women with a personal and family history of breast cancer. Journal of Clinical Oncology 2001 (ct1;19(19):3938-43. PMID: 11579114 (PubMed - indexed for MEDLINE)

National Institutes of Health Consensus Development Panel: National Institutes of Health Consensus Development Conference Statement. Adjuvant Therapy for Breast Cancer 1-3, 2000. Journal of the National Cancer Institute Vol. 93, No. 13, July 14, 2001, 979-89.

Pooled analysis of prospective cohort studies of height, weight, and breast cancer risk. American Journal of Epidemiology 2000; 152: 514-27.
 

CME Viewer Evaluation Form
Please complete the Continuing Medical Education online questionnaire.  The evaluation form provides each viewer the opportunity to rate the extent to which the educational objectives were met, the quality of the instructional process, the perception of enhanced professional effectiveness, the perception of commercial bias and his/her views on future education needs. To indicate your answers use the rating scale shown below by entering the number that represents your answer into the box to the right of each question. To move to the next question use your tab button. When you have completed the evaluation, please click on the "Take test" button at the bottom of the page.

1= none or not at all 2= very little 3= average 4= considerably 5= completely

1. Please rate the degree to which this program's objectives were attained:
• Describe trends in breast cancer incidence and mortality in the U.S. by ethnic group and age  

• Identify selective exposures related to risk of breast cancer   

• Identify women at high risk of developing invasive breast cancer and strategies to decrease this risk   

• Discuss future directions in breast cancer research 

2. The quality of the instructional process was an asset to the program.

3. To what extent did participating in this activity enhance your professional effectiveness?

4. Please rate the quality of the graphics.

5. The instructions provided for the post test were clear and easy to follow.

6.  To what extent did the video: 
• Modify your opinion in this field?
• Modify your practice in this field?
• Reinforce your opinions in this field?
• Prepare you for your practice in this field?       

7.  Please rate the level of commercial bias in this educational activity.  

8.  Other topics you would like to see on video:

9.  Comments/suggestions:

Now that you have completed the evaluation, click below to take the test.